CClinicalTrials.gg
CompletedNCT03778723Updated Sep 4, 2020

Effect of Propofol Midazolam on Cerebral Oxygenation and Metabolism During Clipping of Ruptured Cerebral Aneurysm

An interventional study of Total intravenous anesthesia (TIVA) and Inhalation Anesthesia in Ruptured Cerebral Aneurysm, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-09-04.

Sponsored by Mansoura University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

Despite the theoretical benefits of i.v. agents, volatile agents remain popular. In a study comparing desflurane, isoflurane, and sevoflurane in a porcine model of intracranial hypertension, at equipotent doses and normocapnia, cerebral blood flow (CBF) and ICP were least with sevoflurane.

Propofol is the most commonly used intravenous anesthetic. It has many theoretical advantages by reducing cerebral blood volume (CBV) and ICP and preserving both autoregulation and vascular reactivity. Neurosurgical patients anaesthetized with propofol were found to have lower ICP and higher CPP than those anaesthetized with isoflurane or sevoflurane.

The well known pharmacodynamic advantages of intravenous anesthetics may give this group of drugs superior cerebral effects when compared with inhalation anesthetics.

Read the detailed description

The aim of this study is to evaluate the cerebral hemodynamics and global cerebral oxygenation as well as the systemic hemodynamic changes using midazolam and propofol as total intravenous anesthetics (TIVA) in comparison with sevoflurane anesthesia in clipping of ruptured cerebral aneurysm.

02

Conditions studied

  • Ruptured Cerebral Aneurysm
03

In context

Intracranial Aneurysm

427 studies on the registry are indexed under Intracranial Aneurysm; 114 are open to participants now.

This study's enrollment of 50 is below the median of 110 across 207 interventional studies indexed under Intracranial Aneurysm.

Browse Intracranial Aneurysm studies →

Lead sponsor

Mansoura University is the lead sponsor of 1,077 studies on the registry; 182 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • American Society of Anesthesiologists physical status III or IV.

Exclusion criteria

Exclusion Criteria:

  • Morbid obese patients.
  • Severe or uncompensated cardiovascular diseases
  • Severe or decompensated renal diseases
  • Severe or decompensated hepatic diseases
  • Severe or decompensated endocrinal diseases.
  • Pregnancy
  • Postpartum
  • Lactating females
  • Allergy to one of the agents used.
  • Severely altered consciousness level.
  • Sitting or prone position during surgery.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Total intravenous anesthesia (TIVA)

    Patients will receive total intravenous anesthesia using Propofol and Midazolam

    Drug: Total intravenous anesthesia (TIVA) · Drug: Rescue fentanyl

  • Active comparator
    Inhalation Anesthesia

    Patients will receive Inhalation anesthesia using Sevoflurane

    Drug: Inhalation Anesthesia · Drug: Rescue fentanyl

Interventions

  • DrugTotal intravenous anesthesia (TIVA)

    Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion

  • DrugInhalation Anesthesia

    Sevoflurane at a concentration of 2-2.5%

  • DrugRescue fentanyl

    Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia

06

What researchers measure

Primary outcomes

  1. Arterio-Jugular oxygen content difference

    The differences between arterial and jugular bulb oxygen contents

    Time frame: Immediately before and every 30 min for 6 hour following start of surgery

  2. Estimated cerebral metabolic rate for O2 (eCMRO2)

    eCMRO2=Ca- jO2 x(PaCO2 ∕ 100), Where Ca jO2 is arterio-jugular O2 content difference. PaCO2 is arterial CO2 tension

    Time frame: Immediately before and every 30 min for 6 hour following start of surgery

  3. Cerebral Extraction Rate of O2 (CEO2)

    Calculated as the differences between arterial and jugular bulb O2 saturations, CEO2 = SaO2 - SjvO2

    Time frame: Immediately before and every 30 min for 6 hour following start of surgery

  4. Cerebral Blood Flow equivalent (CBFe)

    : Which is an index of flow metabolism relationship, calculated as a reciprocal of arterio-jugular O2 content difference. CBFe = 1 ∕CaO2-CjvO.

    Time frame: Immediately before and every 30 min for 6 hour following start of surgery

Secondary outcomes

  1. Heart rate

    Time frame: Immediately before and every 30 min for 6 hour following start of surgery

  2. Mean arterial blood pressure

    Time frame: Immediately before and every 30 min for 6 hour following start of surgery

  3. Peripheral oxygen saturation

    Time frame: Immediately before and every 30 min for 6 hour following start of surgery

  4. Central venous pressure

    Time frame: Immediately before and every 30 min for 6 hour following start of surgery

  5. End tidal carbon dioxide tension

    Time frame: Immediately before and every 30 min for 6 hour following start of surgery

  6. Sedation score

    - Postoperative level of sedation of all patients will be evaluated using Ramsay sedation scale

    Time frame: For 6 hours from induction of anesthesia

  7. Time for first analgesic request from extubation

    Time for first analgesic request from extubation

    Time frame: For 6 hours from induction of anesthesia

  8. Duration of stay in intensive care unit

    Time frame: For 5 days after surgery

07

Study locations

1 site
  • Sherif A Mousa
    Mansourah, DK 050, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03778723
Lead sponsor
Mansoura University
Responsible party
Sponsor
First posted
Dec 19, 2018
Start date
Dec 18, 2018
Primary completion
Dec 15, 2019
Completion
Jan 10, 2020
Last update
Sep 4, 2020

Study contacts

Sherif A Mousa, MD
study chair · Professor
Mohammed A Ghanem, MD
study director · Associate Professor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion